Scholars@Duke

• Background
• 

  Education, Training, & Certifications

  • Fellowship in Pediatric Neuropsychiatry, Psychiatry, University of North Carolina, Chapel Hill, School of Medicine 1993 - 1994
  • Fellowship in Child and Adolescent Psychiatry, Psychiatry, University of North Carolina, Chapel Hill, School of Medicine 1991 - 1993
  • General Psychiatry Residency, Psychiatry, University of North Carolina, Chapel Hill, School of Medicine 1988 - 1992
  • M.D., University of Rochester, School of Medicine and Dentistry 1988
• Publications & Artistic Works
• 

  Selected Publications

  • Academic Articles

    • Berry-Kravis, Elizabeth, Joseph P. Horrigan, Nicole Tartaglia, Randi Hagerman, Alexander Kolevzon, Craig A. Erickson, Shivkumar Hatti, et al. “A Double-Blind, Randomized, Placebo-Controlled Clinical Study of Trofinetide in the Treatment of Fragile X Syndrome.” Pediatr Neurol 110 (September 2020): 30–41. https://doi.org/10.1016/j.pediatrneurol.2020.04.019.
       Full Text  Link to Item
    • Dawson, Geraldine, Jessica M. Sun, Jennifer Baker, Kimberly Carpenter, Scott Compton, Megan Deaver, Lauren Franz, et al. “A Phase II Randomized Clinical Trial of the Safety and Efficacy of Intravenous Umbilical Cord Blood Infusion for Treatment of Children with Autism Spectrum Disorder.” J Pediatr 222 (July 2020): 164-173.e5. https://doi.org/10.1016/j.jpeds.2020.03.011.
       Full Text  Link to Item
    • Anagnostou, Evdokia, Nancy Jones, Marisela Huerta, Alycia K. Halladay, Paul Wang, Lawrence Scahill, Joseph P. Horrigan, et al. “Measuring social communication behaviors as a treatment endpoint in individuals with autism spectrum disorder.” Autism 19, no. 5 (July 2015): 622–36. https://doi.org/10.1177/1362361314542955.
       Full Text  Link to Item
    • Jarskog, L Fredrik, Martin T. Lowy, Richard A. Grove, Richard S. E. Keefe, Joseph P. Horrigan, M Patricia Ball, Alan Breier, et al. “A Phase II study of a histamine H₃ receptor antagonist GSK239512 for cognitive impairment in stable schizophrenia subjects on antipsychotic therapy.” Schizophr Res 164, no. 1–3 (May 2015): 136–42. https://doi.org/10.1016/j.schres.2015.01.041.
       Full Text  Link to Item
    • Scahill, Lawrence, Michael G. Aman, Luc Lecavalier, Alycia K. Halladay, Somer L. Bishop, James W. Bodfish, Sabrina Grondhuis, et al. “Measuring repetitive behaviors as a treatment endpoint in youth with autism spectrum disorder.” Autism 19, no. 1 (January 2015): 38–52. https://doi.org/10.1177/1362361313510069.
       Full Text  Link to Item
    • Lecavalier, Luc, Jeffrey J. Wood, Alycia K. Halladay, Nancy E. Jones, Michael G. Aman, Edwin H. Cook, Benjamin L. Handen, et al. “Measuring anxiety as a treatment endpoint in youth with autism spectrum disorder.” J Autism Dev Disord 44, no. 5 (May 2014): 1128–43. https://doi.org/10.1007/s10803-013-1974-9.
       Full Text  Link to Item

  • Conference Papers

    • Snape, Michael F., Joseph P. Horrigan, Robert M. J. Deacon, Michael J. Hurley, and Patricia Cogram. “5.16 AMO-01 in the SHANK3 Knockout Transgenic Mouse Model of Phelan Mcdermid Syndrome.” In Journal of the American Academy of Child & Adolescent Psychiatry, 56:S258–59. Elsevier BV, 2017. https://doi.org/10.1016/j.jaac.2017.09.299.
       Full Text
    • Jarskog, F Fredrik, Richard A. Grove, Joseph P. McEvoy, Richard S. E. Keefe, Martin T. Lowy, Joseph P. Horrigan, and Margaret A. Peykamian. “Randomized, Double-Blind, Placebo Controlled, Parallel Group Exploratory Study of GSK239512 for Cognitive Impairment in Stable Schizophrenia Subjects on Background Antipsychotic Therapy.” In Biological Psychiatry, 71:63S-64S. ELSEVIER SCIENCE INC, 2012.
       Link to Item

Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.